Top

BMC Cancer

Published in:

01-12-2021 | Hepatocellular Carcinoma | Research

Serum epidermal growth factor-like domain 7 serves as a novel diagnostic marker for early hepatocellular carcinoma

Authors: Meng-Yuan Yang, Fan Wu, Feng Fang, Hao Yang, Jing-Fan Zhang, Guo-Dong Chen, Lian-Yue Yang

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Epidermal growth factor-like domain 7 (Egfl7), a recently identified secreted protein, was significantly increased in patients with HCC by our previous studies. However, its efficacy in the diagnosis of early HCC remains unknown. In this study, we therefore evaluate the efficacy of serum Egfl7 for early HCC diagnosis and compare it with alpha-fetoprotein (AFP).

Methods

Serum Egfl7 levels in testing cohort (1081 participants) and validation cohort (476 participants) were measured by a sandwich enzyme-linked immunoassay (ELISA). The cut-off value of Egfl7 was determined by Youden’s index and the efficacies of Egfl7 and AFP in diagnosing early HCC were estimated by receiver operating characteristic (ROC).

Results

Serum Egfl7 was significantly elevated in patients with early HCC than all non-HCC controls in whatever Testing Cohort or Validation Cohort. In the Testing Cohort, ROC curves showed the optimum cut-off value of Egfl7 was 2610 ng/mL and Egfl7 showed a significantly higher sensitivity than AFP in discriminating early HCC from healthy individuals (77.4% vs. 65.3%, P = 0.0013) but the area under ROC (AUROC) and accuracy of Egfl7 and AFP were similar (0.860 vs. 0.868, P = 0.704; 80.2% vs. 83.8%, P = 0.184). In distinguishing patients with early HCC from patients with chronic liver disease (CLD), the AUROC, sensitivity, specificity and accuracy of Egfl7 were 0.800, 75.2, 71.7 and 73.5%, which were all significantly higher than AFP (0.675, 61.8, 62.0 and 61.9% in order). Egfl7 also showed a significant higher sensitivity and accuracy than AFP (76.6% vs. 64.0%, P = 0.0031; 79.9% vs. 66.1%, P < 0.0001) in differentiating early HCC patients from non-HCC individuals. Additionally, 70.8% of early HCC patients with negative AFP could be diagnosed by Egfl7 and the combined use of Egfl7 and AFP increased the sensitivity to 91.0%. These results were confirmed by a validation cohort.

Conclusion

Egfl7 is a valuable serum marker in the diagnosis of early HCC and could complement the efficacy of AFP, especially in distinguishing early HCC from CLD and identifying patients with AFP-negative early HCC.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.CrossRefPubMed

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. https://doi.org/10.3322/caac.21262.CrossRefPubMed

MacLachlan JH, Cowie BC. Hepatitis B virus epidemiology. Cold Spring Harb Perspect Med. 2015;5(5):a021410. https://doi.org/10.1101/cshperspect.a021410.CrossRefPubMedPubMedCentral

Thein HH, Isaranuwatchai W, Campitelli MA, Feld JJ, Yoshida E, Sherman M, et al. Health care costs associated with hepatocellular carcinoma: a population-based study. Hepatology. 2013;58(4):1375–84. https://doi.org/10.1002/hep.26231.CrossRefPubMed

Fujiwara N, Friedman SL, Goossens N, Hoshida Y. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol. 2018;68(3):526–49. https://doi.org/10.1016/j.jhep.2017.09.016.CrossRefPubMed

Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019;156(2):477–91. https://doi.org/10.1053/j.gastro.2018.08.065.CrossRefPubMed

Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335–74. https://doi.org/10.1002/hep.22759.CrossRefPubMed

Chou R, Cuevas C, Fu R, Devine B, Wasson N, Ginsburg A, et al. Imaging techniques for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Ann Intern Med. 2015;162(10):697–711. https://doi.org/10.7326/M14-2509.CrossRefPubMed

Burrel M, Llovet JM, Ayuso C, Iglesias C, Sala M, Miquel R, et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology. 2003;38(4):1034–42. https://doi.org/10.1002/hep.1840380430.CrossRefPubMed

10.

Debruyne EN, Delanghe JR. Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. Clin Chim Acta. 2008;395(1-2):19–26. https://doi.org/10.1016/j.cca.2008.05.010.CrossRefPubMed

11.

Tamura Y, Suda T, Arii S, Sata M, Moriyasu F, Imamura H, et al. Value of highly sensitive fucosylated fraction of alpha-fetoprotein for prediction of hepatocellular carcinoma recurrence after curative treatment. Dig Dis Sci. 2013;58(8):2406–12. https://doi.org/10.1007/s10620-013-2661-6.CrossRefPubMed

12.

Gebo KA, Chander G, Jenckes MW, Ghanem KG, Herlong HF, Torbenson MS, et al. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology. 2002;36(5 Suppl 1):S84–92. https://doi.org/10.1053/jhep.2002.36817.CrossRefPubMed

13.

Daniele B, Bencivenga A, Megna AS, Tinessa V. α-Fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology. 2004;127(5):S108–12. https://doi.org/10.1053/j.gastro.2004.09.023.CrossRefPubMed

14.

Sun T, Tang Y, Sun D, Bu Q, Li P. Osteopontin versus alpha-fetoprotein as a diagnostic marker for hepatocellular carcinoma: a meta-analysis. Onco Targets Ther. 2018;11:8925–35. https://doi.org/10.2147/OTT.S186230.CrossRefPubMedPubMedCentral

15.

Sturgeon CM, Duffy MJ, Hofmann BR, Lamerz R, Fritsche HA, Gaarenstroom K, et al. National Academy of Clinical Biochemistry Laboratory medicine practice guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem. 2010;56(6):e1–48. https://doi.org/10.1373/clinchem.2009.133124.CrossRefPubMed

16.

Mao Y, Yang H, Xu H, Lu X, Sang X, du S, et al. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut. 2010;59(12):1687–93. https://doi.org/10.1136/gut.2010.214916.CrossRefPubMed

17.

Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo KJ, Lee SD, et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med. 1984;310(22):1427–31. https://doi.org/10.1056/NEJM198405313102204.CrossRefPubMed

18.

Soroida Y, Ohkawa R, Nakagawa H, Satoh Y, Yoshida H, Kinoshita H, et al. Increased activity of serum mitochondrial isoenzyme of creatine kinase in hepatocellular carcinoma patients predominantly with recurrence. J Hepatol. 2012;57(2):330–6. https://doi.org/10.1016/j.jhep.2012.03.012.CrossRefPubMed

19.

Taketa K, Sekiya C, Namiki M, Akamatsu K, Ohta Y, Endo Y, et al. Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions. Gastroenterology. 1990;99(2):508–18. https://doi.org/10.1016/0016-5085(90)91034-4.CrossRefPubMed

20.

Kumada T, Nakano S, Takeda I, Kiriyama S, Sone Y, Hayashi K, et al. Clinical utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in small hepatocellular carcinoma: special reference to imaging diagnosis. J Hepatol. 1999;30(1):125–30. https://doi.org/10.1016/S0168-8278(99)80016-6.CrossRefPubMed

21.

Yamashiki N, Seki T, Wakabayashi M, Nakagawa T, Imamura M, Tamai T, et al. Usefulness of Lens culinaris agglutinin A-reactive fraction of alpha-fetoprotein (AFP-L3) as a marker of distant metastasis from hepatocellular carcinoma. Oncol Rep. 1999;6(6):1229–32. https://doi.org/10.3892/or.6.6.1229.CrossRefPubMed

22.

Xu D, Su C, Sun L, Gao Y, Li Y. Performance of serum Glypican 3 in diagnosis of hepatocellular carcinoma: a meta-analysis. Ann Hepatol. 2019;18(1):58–67. https://doi.org/10.5604/01.3001.0012.7863.CrossRefPubMed

23.

Li B, Li B, Guo T, et al. The clinical values of serum markers in the early prediction of hepatocellular carcinoma. Biomed Res Int. 2017;2017:5358615.PubMedPubMedCentral

24.

Shen Q, Fan J, Yang XR, Tan Y, Zhao W, Xu Y, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol. 2012;13(8):817–26. https://doi.org/10.1016/S1470-2045(12)70233-4.CrossRefPubMed

25.

Yang H, Chen GD, Fang F, Liu Z, Hiu Yan Lau S, Zhang JF, et al. Dickkopf-1: as a diagnostic and prognostic serum marker for early hepatocellular carcinoma. Int J Biol Markers. 2013;28(3):286–97. https://doi.org/10.5301/JBM.5000015.CrossRefPubMed

26.

Fitch MJ, Campagnolo L, Kuhnert F, Stuhlmann H. Egfl7, a novel epidermal growth factor-domain gene expressed in endothelial cells. Dev Dyn. 2004;230(2):316–24. https://doi.org/10.1002/dvdy.20063.CrossRefPubMedPubMedCentral

27.

Nikolic I, Stankovic ND, Bicker F, et al. EGFL7 ligates αvβ3 integrin to enhance vessel formation. Blood. 2013;121(15):3041–50. https://doi.org/10.1182/blood-2011-11-394882.CrossRefPubMed

28.

Schmidt M, Paes K, De Mazière A, et al. EGFL7 regulates the collective migration of endothelial cells by restricting their spatial distribution. Development. 2007;134(16):2913–23. https://doi.org/10.1242/dev.002576.CrossRefPubMed

29.

Nichol D, Stuhlmann H. EGFL7: a unique angiogenic signaling factor in vascular. Blood. 2012;119(6):1345–52. https://doi.org/10.1182/blood-2011-10-322446.CrossRefPubMedPubMedCentral

30.

Parker LH, Schmidt M, Jin SW, Gray AM, Beis D, Pham T, et al. The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation. Nature. 2004;428(6984):754–8. https://doi.org/10.1038/nature02416.CrossRefPubMed

31.

Wu F, Yang LY, Li YF, Ou DP, Chen DP, Fan C. Novel role for epidermal growth factor-like domain 7 in metastasis of human hepatocellular carcinoma. Hepatology. 2009;50(6):1839–50. https://doi.org/10.1002/hep.23197.CrossRefPubMed

32.

Fan C, Yang LY, Wu F, Tao YM, Liu LS, Zhang JF, et al. The expression of Egfl7 in human normal tissues and epithelial tumors. Int J Biol Markers. 2013;28(1):71–83. https://doi.org/10.5301/JBM.2013.10568.CrossRefPubMed

33.

Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150(4):835–53. https://doi.org/10.1053/j.gastro.2015.12.041.CrossRefPubMed

34.

Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–99. https://doi.org/10.1002/hep.29800.CrossRefPubMed

35.

Ghany MG, Morgan TR, AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology. 2020;71(2):686–721. https://doi.org/10.1002/hep.31060.CrossRefPubMed

36.

Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. Radiology. 2015;277(3):826–32. https://doi.org/10.1148/radiol.2015151516.CrossRefPubMed

37.

Luo P, Yin P, Hua R, Tan Y, Li Z, Qiu G, et al. A large-scale, multi-center serum metabolite biomarkers identification study for the early detection of hepatocellular carcinoma. Hepatology. 2018;67(2):662–75. https://doi.org/10.1002/hep.29561.CrossRefPubMed

38.

Nguyen MH, Garcia RT, Simpson PW, Wright TL, Keeffe EB. Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis. Hepatology. 2002;36(2):410–7. https://doi.org/10.1053/jhep.2002.34744.CrossRefPubMed

39.

Li D, Sedano S, Allen R, et al. Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life. Cancers. 2019;11:841.CrossRefPubMedCentral

40.

Chang Y, Lairson DR, Chan W, Lu SN, Aoki N. Cost-effectiveness of screening for hepatocellular carcinoma among subjects at different levels of risk. J Eval Clin Pract. 2011;17(2):261–7. https://doi.org/10.1111/j.1365-2753.2010.01432.x.CrossRefPubMed

41.

Stefaniuk P, Cianciara J, Wiercinska-Drapalo A. Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J Gastroenterol. 2010;6:418–24.CrossRef

42.

Kokudo N, Makuuchi M. Evidence-based clinical practice guidelines for hepatocellular carcinoma in Japan: the J-HCC guidelines. J Gastroenterol. 2009;44(Suppl 19):119–21. https://doi.org/10.1007/s00535-008-2244-z.CrossRefPubMed

43.

García-Fernández N, Macher HC, Rubio A, et al. Detection of p53 mutations in circulating DNA of transplanted hepatocellular carcinoma patients as a biomarker of tumor recurrence. Adv Exp Med Biol. 2016;924:25–8. https://doi.org/10.1007/978-3-319-42044-8_5.CrossRefPubMed

44.

Zhang C, Ge S, Wang J, Jing X, Li H, Mei S, et al. Epigenomic profiling of DNA methylation for hepatocellular carcinoma diagnosis and prognosis prediction. J Gastroenterol Hepatol. 2019;34(10):1869–77. https://doi.org/10.1111/jgh.14694.CrossRefPubMed

45.

Zhou J, Yu L, Gao X, Hu J, Wang J, Dai Z, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol. 2011;29(36):4781–8. https://doi.org/10.1200/JCO.2011.38.2697.CrossRefPubMed

46.

Xu H, Chen Y, Dong X, Wang X. Serum exosomal long noncoding RNAs ENSG00000258332.1 and LINC00635 for the diagnosis and prognosis of hepatocellular carcinoma. Cancer Epidemiol Biomark Prev. 2018;27(6):710–6. https://doi.org/10.1158/1055-9965.EPI-17-0770.CrossRef

47.

Zhang X, Xu Y, Qian Z, et al. circRNA_104075 stimulates YAP-dependent tumorigenesis through the regulation of HNF4a and may serve as a diagnostic marker in hepatocellular carcinoma. Cell Death Dis. 2018;9:1091.CrossRefPubMedPubMedCentral

48.

Malaguarnera G, Giordano M, Paladina I, Berretta M, Cappellani A, Malaguarnera M. Serum markers of hepatocellular carcinoma. Dig Dis Sci. 2010;55(10):2744–55. https://doi.org/10.1007/s10620-010-1184-7.CrossRefPubMed

49.

Liu XJ, Wang B, Jiang WG, Li YJ, Liu JB, Zhang M. Multivariate analysis of molecular markers in peripheral blood associated with recurrence and metastasis of hepatocellular carcinoma. Genet Mol Res. 2015;14(1):1502–7. https://doi.org/10.4238/2015.February.20.5.CrossRefPubMed

50.

Shen X, Han Y, Xue X, Li W, Guo X, Li P, et al. Epidermal growth factor-like domain 7 promotes cell invasion and angiogenesis in pancreatic carcinoma. Biomed Pharmacother. 2016;77:167–75. https://doi.org/10.1016/j.biopha.2015.12.009.CrossRefPubMed

51.

Hansen TF, Andersen RF, Olsen DA, Sørensen FB, Jakobsen A. Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab. Sci Rep. 2017;7(1):2388. https://doi.org/10.1038/s41598-017-02538-x.CrossRefPubMedPubMedCentral

52.

Jia X, Liu J, Gao Y, Huang Y, du Z. Diagnosis accuracy of serum glypican-3 in patients with hepatocellular carcinoma: a systematic review with meta-analysis. Arch Med Res. 2014;45(7):580–8. https://doi.org/10.1016/j.arcmed.2014.11.002.CrossRefPubMed

53.

Marrero JA, Romano PR, Nikolaeva O, Steel L, Mehta A, Fimmel CJ, et al. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol. 2005;43(6):1007–12. https://doi.org/10.1016/j.jhep.2005.05.028.CrossRefPubMed

54.

Zhang Z, Zhang Y, Wang Y, et al. Alpha-fetoprotein-L3 and Golgi protein 73 may serve as candidate biomarkers for diagnosing alpha-fetoprotein-negative hepatocellular carcinoma. Onco Targets Ther. 2015;9:123–9.PubMedPubMedCentral

Title: Serum epidermal growth factor-like domain 7 serves as a novel diagnostic marker for early hepatocellular carcinoma
Authors: Meng-Yuan Yang
Fan Wu
Feng Fang
Hao Yang
Jing-Fan Zhang
Guo-Dong Chen
Lian-Yue Yang
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Hepatocellular Carcinoma
Benign Liver Tumors
Hepatocellular Carcinoma
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08491-3

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Image Credits

ASCO 2024 | Highlights of the Day: Breast cancer – metastatic/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Gynecologic Cancer/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Breast Cancer – local/regional/adjuvant/© 2024 American Society of Clinical Oncology, all rights reserved., Melanoma/© selvanegra / Getty Images / iStock, Antibody drug conjugated with cytotoxic payload/© Love Employee / Getty images / iStock

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Development and validation of an immune gene-set based prognostic signature for soft tissue sarcoma

Comprehensive analysis of DNA damage repair genes reveals pathogenic variants beyond BRCA and suggests the need for extensive genetic testing in pancreatic cancer

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M

Toward developing a metastatic breast cancer treatment strategy that incorporates history of response to previous treatments

Oxaliplatin plus S-1 with intraperitoneal paclitaxel for the treatment of Chinese advanced gastric cancer with peritoneal metastases